Biopharma leaders condemned the actions of the mob that stormed Capitol Hill on Wednesday. On social media and in statements, leading voices in the industry expressed indignation and disappointment, with Pfizer CEO Albert Bourla calling it “deeply disturbing.” (Endpoints News)

With Democrats claiming a narrow majority in the Senate, the door is open to changes to health policy, like expanding or clarifying parts of the Affordable Care Act. But major health reform may prove a bit more difficult. (The New York Times)

A record number of Americans died from COVID-19 on Wednesday. More than 3,800 lives were lost, representing the highest daily death count so far in the U.S., according to data from Johns Hopkins University. (CNBC Weekly)

Bayer AG will collaborate with CureVac NV to develop a COVID-19 vaccine, the companies announced. The companies plan to manufacture hundreds of millions of doses and distribute them within the EU and in additional markets. (The Wall Street Journal)

Biotech entrepreneur John Hood’s new company, Endeavor BioMedicines, raised $62 million to test a drug’s efficacy against lung disease. Hood’s previous company, Impact Biomedicines, was sold to Celgene in January 2018 for $2 billion. (STAT)